



1648

Atty Dkt No. PP1617.002
2300-1617
PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 14 Nov 2001

11/14/01 Susan LaMont
Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Art Unit: 1648

Filing Date: November 22, 2000

Examiner: S. Brown

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

AMENDMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JAN 09 2002
TECH CENTER 1600/2900

Sir:

Transmitted herewith for filing is a Response to Restriction Requirement in the above patent application in response to the Office Action of October 15, 2001.

 Petition for Extension of Time enclosed.

 X No additional fee is required.

 X Also enclosed: postcard

No. of Claims After Amendment	Most Claims Previously Paid			Extra Claims			Additional Fee		
A. Total Claims		-		=		x	\$18	=	\$
B. Ind. Claims		-		=		x	\$84	=	
C. If amended to contain multiple dependent claims, add 280							\$280	=	\$
D. Total Amendment Fee (Total of A, B & C)								=	
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								=	

F. Total Amendment Fee (D minus E)	=	\$
------------------------------------	---	----

— A check for \$ to cover the extension of time fee and extra claims fee is attached.

— Charge \$ to Deposit Account No. 18-1648.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: Nov 14, 2001

By: *Dahna S. Pasternak*
Dahna S. Pasternak
Registration No. 41,411
Attorney for Applicants

ROBINS & PASTERNAK LLP
90 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: 650-325-7812
Facsimile: 650-325-7823



Atty Dkt PP1617.002
2300-1617
PATENT

*#20
Elect
addressing*

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 14 Nov 2001

11/14/01
Date

Susan LaMont
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Group Art Unit: 1648

Filing Date: November 22, 2000

Examiner: S. Brown

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the second Restriction Requirement dated October 15, 2001 (Paper No. 19) wherein the Examiner required election of one of the following groups of claims:

Group I (claims 1-19 and 32), drawn to an HCV polypeptide;

Group II (claims 20-31), drawn to an HCV polynucleotide;

Group III (claims 33-37), drawn to a method of preparing an HCV polypeptide;

Group IV (claims 38-40), drawn to an antibody that binds to an HCV polypeptide;

Group V (claim 41), drawn to a method of eliciting an immune response comprising administering a polypeptide; and

Group VI (claim 42), drawn to a method of eliciting an immune response comprising administering a polynucleotide.

Applicants hereby elect to prosecute the claims of Group I, claims 1-19 and 32, with traverse.

RECEIVED
JAN 09 2002
TECH CENTER 1600/2300

In support of the restriction requirement, the Examiner asserts that the claims of each group are patentably distinct. However, Applicants note that two criteria must be met for a proper restriction requirement under M.P.E.P. § 803: (1) the inventions must be independent or distinct as claimed; and (2) there must be a serious burden on the Examiner if restriction is not required. Applicants respectfully submit that the Examiner has not met this burden.

In particular, the Examiner has not shown that it would impart a serious burden to examine the claims of Groups I and II together or the claims of Groups III to VI together. Applicants respectfully point out that the allegedly distinct inventions of Groups III and VI share the same classification (Class 435) while Groups IV and V are both classified in Class 424. Additionally, Applicants note that the claims in all of the allegedly distinct depend ultimately from claim 1 (Group I). In view of the close interrelatedness of the claimed inventions, it would not be a serious burden on the Examiner to search and examine the inventions of Groups I and II (HCV polypeptides and polynucleotides encoding these polypeptides) together as well as Groups III and VI (methods of preparing HCV polypeptides, methods of eliciting an immune response using the claimed HCV polypeptides or polynucleotides encoding these polypeptides) together, especially in light of the fact that all pending claims depend from either claim 1 (Group I).

In sum, applicants submit that the Restriction Requirement be redefined to combine, at a minimum, Groups I to II as one group and Groups V and VI as another. As acknowledged by the Examiner's classification, the search required for each of these Groups would reveal art relevant to other Group. Therefore, examination of these allegedly distinct inventions in one application would not only not place an undue burden on the Examiner, but would actually save the Examiner time.

Applicants expressly reserve their right under 35 USC §121 to file one or more divisional applications directed to the nonelected subject matter during the pendency of this application.

Please direct all further communications regarding this application to:

Alisa A. Harbin, Esq.
Chiron Corporation
Intellectual Property - R440
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-2719
Facsimile: (510) 655-3542

Respectfully submitted,

Date: Nov 14, 2001

By: D. Pasternak
Dahna S. Pasternak
Registration No. 41,411

CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 932-2708
Fax: (510) 655-3542